CytoDyn Inc. (OTCMKTS:CYDY) Sees Large Increase in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 16,577,600 shares, an increase of 25.8% from the October 15th total of 13,179,400 shares. Based on an average trading volume of 6,265,900 shares, the short-interest ratio is currently 2.6 days.

CytoDyn Price Performance

OTCMKTS CYDY remained flat at $0.12 during trading on Friday. The company’s stock had a trading volume of 3,225,027 shares, compared to its average volume of 2,584,065. The company has a market capitalization of $147.79 million, a price-to-earnings ratio of -6.15 and a beta of 0.17. CytoDyn has a 12-month low of $0.11 and a 12-month high of $0.42. The stock has a fifty day moving average price of $0.14 and a two-hundred day moving average price of $0.15.

CytoDyn (OTCMKTS:CYDY) last posted its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.